高级检索
当前位置: 首页 > 详情页

Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China [b]Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China [c]Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China [d]Chinese GRADE Center, Lanzhou, China [e]WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou, China [f]Standardization Project Management Office of China Association of Traditional Chinese Medicine, Beijing, China [g]The First Affiliated Hospital of Guangzhou Medical University, The First Clinical School of Guangzhou Medical University, Guangzhou, China [h]Guangzhou Institute of Respiratory Disease, Guangzhou, China [i]State Key Laboratory of Respiratory Disease, Guangzhou, China [j]National Clinical Research Center for Respiratory Disease, Guangzhou, China
出处:
ISSN:

摘要:
Influenza is a major public health problem worldwide. Mutations and resistance development make the use of antiviral therapy challenging. Chinese patent medicines are often used to treat influenza in China and well tolerable. However, the misuse of Chinese patent medicines is common. We therefore aimed to develop an evidence-based guideline on treating influenza with Chinese patent medicines in adults to guide clinical practice. We formed a steering committee, a consensus panel, a consultants' group and an evidence synthesis team to guide the development of the guideline. We formulated the clinical questions through two rounds of survey, and finally selected five questions. We then systematically searched the related evidence and conducted meta-analyses, evidence summaries and GRADE decision tables to draft the recommendations, which the consensus panel then voted on using the Delphi method. Finally, we formulated six recommendations based on the evidence synthesis and experts' consensus. For treating mild influenza, we suggest either Lianhua Qingwen capsule, Jinhua Qinggan granule, Banlangen granule, Shufeng Jiedu capsule, or Jinfang Baidu pill, depending on the manifestations. For severe influenza, or mild influenza in patients at high risk of developing severe influenza, we suggest Lianhua Qingwen capsule in combination with antiviral medications and supportive therapy. The strength of all recommendations was weak. Traditional Chinese medicine has great potential to help in the fight against influenza worldwide, but more high-quality studies are still needed to strengthen the evidence. Copyright © 2020. Published by Elsevier Ltd.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 1 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 1 区 药学
JCR分区:
出版当年[2018]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [a]The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China [b]Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China
共同第一作者:
通讯作者:
通讯机构: [a]The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China [b]Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China [g]The First Affiliated Hospital of Guangzhou Medical University, The First Clinical School of Guangzhou Medical University, Guangzhou, China [h]Guangzhou Institute of Respiratory Disease, Guangzhou, China [i]State Key Laboratory of Respiratory Disease, Guangzhou, China [j]National Clinical Research Center for Respiratory Disease, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号